EvoRx is a privately held, early stage biotechnology company. It strives to discover and develop innovative peptide therapeutics and targeted radiopharmaceuticals for treatment and diagnosis of disease with high unmet medical need. Its proprietary Evo-LinkĀ technology rapidly generates remarkably high diversity cyclic peptide libraries. The libraries are screened for drug-like activity in environments that mimic the physiological environment of the body. The result is uniquely structured peptides that are highly stable in human serum, that have antibody-like specificity and affinity, and that are also membrane permeable. These features allow target protein interactions previously thought of as "undruggable".
